ANRO

Alto NeuroscienceB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$40.00

+113.8% vs current

Most likely

Base case

45%

Probability

Target price

$24.00

+28.3% vs current

B-

Bear case

30%

Probability

Target price

$14.00

-25.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-18

AI commentary

Sentiment looks cautious rather than broken: the April 1 ALTO-101 readout was a real setback, but the March financing materially reduced near-term balance-sheet risk and left Alto with multiple remaining data shots in 2026. Even so, the deterministic prior stays negative, and the thesis has become narrower and more monitoring-oriented until ALTO-207 starts on time and another program produces cleaner efficacy evidence [#8-K-2026-04-01] [#10-K-2026-03-16].

RankAlpha Sentiment Codex - 2026-04-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventALTO-207 Phase 2b trial initiation in TRDHigh impact

Management said ALTO-207 remains the top priority and the Phase 2b trial is on track to start in 1H 2026, with PIPE proceeds intended to support development through a planned Phase 3 path and potential NDA submission [#10-K-2026-03-16] [#PR-2026-03-16-financing].

2026-07-15catalystALTO-300 Phase 2b MDD topline dataHigh impact

Alto guided to mid-2026 topline data for ALTO-300, one of the remaining near-term readouts after the ALTO-101 miss, so a clean signal could broaden the thesis beyond ALTO-207 while a miss would reinforce single-asset concentration [#10-K-2026-03-16].

2026-11-15catalystALTO-100 Phase 2b bipolar depression topline dataHigh impact

Management still guides to 2H 2026 topline data for ALTO-100, giving ANRO a second independent 2026 clinical swing that can either restore pipeline depth or deepen the post-ALTO-101 narrowing of the story [#10-K-2026-03-16].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-18 • Updated nightlySource: Internal modelMethodology